These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7862461)

  • 1. Reversion of a human tumour cell line containing oncogenic p21ras is associated with a defect in the post-translational processing of the ras protein.
    Tilbrook PA; Paterson HF; Marshall CJ
    Oncogene; 1995 Feb; 10(4):805-9. PubMed ID: 7862461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
    Yan N; Ricca C; Fletcher J; Glover T; Seizinger BR; Manne V
    Cancer Res; 1995 Aug; 55(16):3569-75. PubMed ID: 7627966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of farnesyltransferase and Ras processing peptidase.
    Hall CC; Watkins JD; Ferguson SB; Foley LH; Georgopapadakou NH
    Biochem Biophys Res Commun; 1995 Dec; 217(3):728-32. PubMed ID: 8554591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
    Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against malignant conversion in SENCAR mouse skin by all trans retinoic acid: inhibition of the ras p21-processing enzyme farnesyltransferase and Ha-ras p21 membrane localization.
    Agarwal R; Mohan RR; Ahmad N; Mukhtar H
    Mol Carcinog; 1996 Sep; 17(1):13-22. PubMed ID: 8876671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered post-translational processing of p21ras oncoprotein in a transformation-suppressed cell line.
    Huang S; Axelrod DE
    Oncogene; 1991 Jul; 6(7):1211-8. PubMed ID: 1861867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesyltransferase activity and mRNA expression in human skin basal cell carcinomas.
    Khan SG; Dummer R; Siddiqui J; Bickers DR; Agarwal R; Mukhtar H
    Biochem Biophys Res Commun; 1996 Mar; 220(3):795-801. PubMed ID: 8607844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevation of alpha2(I) collagen, a suppressor of Ras transformation, is required for stable phenotypic reversion by farnesyltransferase inhibitors.
    Du W; Lebowitz PF; Prendergast GC
    Cancer Res; 1999 May; 59(9):2059-63. PubMed ID: 10232587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice.
    Mangues R; Corral T; Kohl NE; Symmans WF; Lu S; Malumbres M; Gibbs JB; Oliff A; Pellicer A
    Cancer Res; 1998 Mar; 58(6):1253-9. PubMed ID: 9515813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of p21Ras-mediated apoptosis induced by protein kinase C inhibition and application to human tumor cell lines.
    Liou JS; Chen JS; Faller DV
    J Cell Physiol; 2004 Feb; 198(2):277-94. PubMed ID: 14603530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti tumor activity of farnesyl transferase inhibitor].
    Yoshimatsu K; Nagasu T
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.
    Nammi S; Lodagala DS
    Acta Pharmacol Sin; 2000 May; 21(5):396-404. PubMed ID: 11324435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors.
    Prendergast GC; Davide JP; Lebowitz PF; Wechsler-Reya R; Kohl NE
    Cancer Res; 1996 Jun; 56(11):2626-32. PubMed ID: 8653708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of protein isoprenylation and p21ras membrane association by dehydroepiandrosterone in human colonic adenocarcinoma cells in vitro.
    Schulz S; Nyce JW
    Cancer Res; 1991 Dec; 51(24):6563-7. PubMed ID: 1835900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GTP loading of farnesylated p21Ras by insulin at the plasma membrane.
    Goalstone M; Leitner JW; Draznin B
    Biochem Biophys Res Commun; 1997 Oct; 239(1):42-5. PubMed ID: 9345266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein prenylation: key to ras function and cancer intervention?
    Khosravi-Far R; Cox AD; Kato K; Der CJ
    Cell Growth Differ; 1992 Jul; 3(7):461-9. PubMed ID: 1419908
    [No Abstract]   [Full Text] [Related]  

  • 19. Farnesylation of p21 Ras proteins in Xenopus oocytes.
    Zhao J; Kung HF; Manne V
    Cell Mol Biol Res; 1994; 40(4):313-21. PubMed ID: 7866432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
    Ghosh PM; Ghosh-Choudhury N; Moyer ML; Mott GE; Thomas CA; Foster BA; Greenberg NM; Kreisberg JI
    Oncogene; 1999 Jul; 18(28):4120-30. PubMed ID: 10435593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.